Seeking Alpha

Roth initiates Acura Pharmaceuticals (ACUR +5.8%) at Buy with a $4.50 price target, representing...

Roth initiates Acura Pharmaceuticals (ACUR +5.8%) at Buy with a $4.50 price target, representing a near 100% upside from Monday's closing price. On the earnings call earlier this month, Roth analyst Robert Cummins Hazlett had a good-natured back-and-forth with management regarding NEXAFED and OXECTA.
Comments (3)
  • ronk105
    , contributor
    Comments (3) | Send Message
     
    Think this company has tremendous upside with recent FDA findings. It just needs a little more help being recognized for what it is trying to accomplish and that is misuse and abuse of drugs that are addictive.
    14 May 2013, 02:11 PM Reply Like
  • Jbgoose
    , contributor
    Comments (1011) | Send Message
     
    That's a good one, 'help being recognized' ...
    This has been achieved a few times, up and down, circled around and around. You have any other favorites in the field?
    14 May 2013, 08:36 PM Reply Like
  • Jbgoose
    , contributor
    Comments (1011) | Send Message
     
    Oh, so there was not much SA noise about the FDA decision on Opana ER generics. This decision to ignore some of the politics makes me curious as to Zohydro again. Perhaps distribution restrictions but it's no longer absolute Dead on Arrival. Liver disease being so extremely problematic to ignore approving a long term safe and effective medication far less 'potent' than others. Shall see, looking to establish a position after further research. Less than the lottery ...
    14 May 2013, 08:50 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|